SB 202474
- CAS NO.:172747-50-1
- Empirical Formula: C17H17N3O
- Molecular Weight: 279.34
- MDL number: MFCD06804624
- Update Date: 2026-04-24 14:58:21
What is SB 202474?
The Uses of SB 202474
SB 202474 is structurally similar to SB 202190 (S154495) and SB 203580 (S154600), which are p38 MAP kinase inhibitors. SB 202747 can be employed in p38 inhibition research.
What are the applications of Application
SB 202474 is a negative control for SB202190 and SB203580 in p38 MAP kinase inhibition studies
Biological Activity
sb 202474 is a structural analog of sb 202190 and sb 203580 that is used as a negative control in researches of p38 inhibition. sb 202190 and sb 203580 are potent and selective inhibitors of the map kinases p38α and p38β [1][2][3].mitogen-activated protein kinases (mapks) are ser/thr-specific protein kinases that regulate gene expression, proliferation, differentiation, cell survival and apoptosis. three most widely characterized mapk subfamilies are erk1/2, jnk and p38mapk, of which jnk and p38mapk are identified as a stress-activated protein kinase (sapk) that primarily mediates inflammatory response and promotes cell death [3].sb 202474 is a structural analog of sb 202190 and sb 203580 that is used as a negative control in researches of p38 inhibition. in 3t3-l1 adipocytes and l6 myotubes, sb203580 but not sb202474 prevented insulin-stimulated glucose transport [2].pretreatment with microinjection into the bilateral rostral ventrolateral medulla (rvlm) of sb203580 (2 nmol) significantly exacerbated the depressor effect and blunted the augmented power density of the lf component of sap signals during the pro-life phase. sb203580 also significantly shortened the pro-life phase to 60 min. sb202474 (2 nmol) was ineffective against the phasic cardiovascular responses in the acsf-control group or mev-experimental group [3].
References
[1]. davies sp, reddy h, caivano m, et al. specificity and mechanism of action of some commonly used protein kinase inhibitors. biochem j. 2000 oct 1;351(pt 1):95-105.
[2]. sweeney g, somwar r, ramlal t, et al. an inhibitor of p38 mitogen-activated protein kinase prevents insulin-stimulated glucose transport but not glucose transporter translocation in 3t3-l1 adipocytes and l6 myotubes. j biol chem. 1999 apr 9;274(15):10071-8.
[3]. chang ay. pro-life role for c-jun n-terminal kinase and p38 mitogen-activated protein kinase at rostral ventrolateral medulla in experimental brain stem death. j biomed sci. 2012 nov 17;19:96.
Properties of SB 202474
| Melting point: | >80°C (dec.) |
| Boiling point: | 520.7±50.0 °C(Predicted) |
| Density | 1.156±0.06 g/cm3(Predicted) |
| storage temp. | -20°C |
| solubility | DMSO (Slightly), Methanol (Slightly) |
| pka | 11.98±0.10(Predicted) |
| form | Off-white solid |
| color | Pale Yellow to Yellow |
Safety information for SB 202474
Computed Descriptors for SB 202474
New Products
9-Mesityl-10-methylacridinium perchlorate Sulfapyridine Fmoc-OSu (R)-(-)-2-Amino-1-propanol Cyclobutanone 5-bromo-4-fluoro-2-nitrobenzaldehyde 4 pentyn 1 ol N-Vinylformamide Phenethyl cinnamate Pyrrolo[1,2-a]pyrimidine-6-carboxylic acid, 4,6,7,8-tetrahydro-4-oxo-, sodium salt (1:1), (6S) Ethyl 3-phenylpropanoate β-Bromostyrene Methacrylate-PEG-Methacrylate, Mn:35000 2,4-Dihydroxyacetophenone 2-Chloro 5-Fluoro Pyridine Vasicinone 2-Chloroisonicotinic Acid Tween 80 or Polysorbate 80 Methyl trans-4-Aminocyclohexanecarboxylate Hydrochloride N-(4-fluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-amine Pirtobrutinib intd. 4-Nitrobenzotrifluoride 2-Pentyn-1-oL N-(4-Cyano-3-(trifluoromethyl)phenyl)-2-methyloxirane-2-carboxamideYou may like
-
1191-95-3 Cyclobutanone 98+View Details
1191-95-3 -
213382-45-7 98+View Details
213382-45-7 -
Fmoc-OSu 98+View Details
82911-69-1 -
(R)-(-)-2-Amino-1-propanol 35320-23-1 98+View Details
35320-23-1 -
1191-95-3 Cyclobutanone 98+View Details
1191-95-3 -
213382-45-7 98+View Details
213382-45-7 -
Fmoc-OSu 98+View Details
82911-69-1 -
(R)-(-)-2-Amino-1-propanol 35320-23-1 98+View Details
35320-23-1
